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Editor’s Choice
THROMBOLYSIS OUTCOMES IN ACUTE
ISCHEMIC STROKE PATIENTS WITH PRIOR
STROKE AND DIABETES MELLITUS
Gaetano Santulli, New York: Mishra et al.1 exam-
ined the influence of diabetes mellitus and prior
stroke on the outcomes of patients who received
thrombolysis vs nonthrombolyzed controls. They
found no interaction on outcome between diabetes
and prior stroke with thrombolysis treatment.
These results conflict with the European Medicines
Evaluation Agency’s justification for restricting the use
of IV alteplase. As Dr. Demaerschalk mentioned in the
accompanying editorial,2 recent studies1,3,4 have sug-
gested that thrombolysis can be safely used in several
groups of patients who do not qualify for treatment due
to strict application of exclusion criteria.
In addition, most of the commonly cited thrombo-
lytic exclusion criteria are just consensus-based, not
evidence-based.2,3 It is time to reevaluate the criteria for
thrombolysis, adopting a clinical score to stratify the
risk, similar to those used in acute coronary syndrome.5
A good risk assessment tool will be able to identify a
gradient of mortality risk by using variables that capture
the majority of prognostic information to better evalu-
ate the risk/benefit ratio for each patient.
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A RANDOMIZED TRIAL OF HIGH-DOSE
VITAMIN D2 IN RELAPSING-REMITTING
MULTIPLE SCLEROSIS
Helmut H. Leitner, Vienna: Stein et al.1 compared
high- vs low-dose vitamin D2 treatment in MS with-
out benefit in the high-dose treatment group. Sun-
light exposure and reduced vitamin D3 levels
independently contribute to MS risk. The effect of
sunlight exposure is supported by decreased signs of
actinic skin damage found in MS patients compared
to controls.2 It is difficult to determine which of
these 2 environmental factors is of primary impor-
tance as higher levels of sunlight exposure will en-
hance vitamin D levels.
The incidence of vitamin D–related rickets dis-
ease decreased in the United States and Europe dur-
ing the last century following the discovery that
vitamin D possessed antirachitic properties, whereas
the incidence of MS seemed to increase in the same
population. In the United States, most of the patients
with rickets are African American, whereas the majority
of patients with MS are of European ancestry.3 It seems
improbable that the same environmental factor should
be centrally involved in the etiology of both diseases,
which differ clinically and occur in different popula-
tions living in the same geographic area.
These findings together with those of Stein et al.
do not provide a reason for vitamin D supplementa-
Editors’ Note: Dr. Santulli, citing the findings of Dr. Mishra
et al. that neither diabetes nor prior stroke affected throm-
bolysis outcomes, calls for the reevaluation of thrombolysis
criteria and the adoption of a clinical score, similar to that
used in acute coronary syndrome, to stratify risk. There were
2 WriteClick submissions in reference to the recent article by
Dr. Stein et al. comparing high-dose and low-dose vitamin
D2 supplementation in relapsing-remitting multiple sclerosis.
Dr. Leitner calls attention to the incongruity of epi-
demiologic trends in MS vs another vitamin D–related
illness, rickets, as further reason not to supplement patients
with MS without proven vitamin D deficiency at this time. Dr.
Grimaldi et al. argue that the study was underpowered and
potentially biased. Their own phase II study of high-dose
vitamin D3 supplementation is under way.
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tion in MS aside from correcting a proven vitamin D
deficiency. Other factors associated with increased
sunlight exposure may more effectively prevent MS.
L. Grimaldi, Cefalu`, Italy; F. Barkhof, Amster-
dam; M. Beelke, Gauting–Unterbrunn, Germany;
J. Burton, Calgary, Canada; T. Holmoy, Oslo; R.
Hupperts, Sittard, the Netherlands; J. Killestein,
Amsterdam; P. Rieckmann, Wurzburg, Germany;
M. Schluep, Lausanne, Switzerland; J. Smolders,
Amsterdam; on behalf of the SOLAR study group:
The conclusion of Stein et al.1 that high-dose ineffec-
tive vs low-dose vitamin D2 supplementation in
relapsing-remitting MS (RRMS) is not supported by
data enabling level 1 evidence.
Randomization to interferon-, glatiramer ace-
tate, or no treatment results in very small treatment
groups. Such MRI-based randomized placebo-
controlled trials would need at least 85 patients per
arm to reach statistical significance, assuming 50%
treatment difference4 and, since vitamin D effects
may appear after 12–24 weeks, an MRI follow-up
period of at least 9—not 6—months.
In figure 2, only 4/11 subjects in the higher dose
group exhibited 25(OH)D levels within the 130–
175 nmol/L target range.1 Since dosages must have
been adjusted continuously throughout the trial,
likely fluctuations in serum 25(OH)D prevent firm
conclusions.5
During the study, MKTVIF75HV (vitamin D2)
was replaced by vitamin D3. As vitamin D2 and D3
are not equivalent,5 these results cannot be extended
to all “vitamin D” subtypes.
To address these issues, an appropriately pow-
ered, randomized, double-blind, placebo-controlled,
phase II study (SOLAR) of high-dose vitamin D3
(vigantol oil, 14,000 IU/d) add-on to interferon
–1a, 44 g subcutaneously 3 times weekly (Rebif),
for 96 weeks in 348 RRMS patients, is currently
under way.6
The SOLAR study group also includes Reinhold Vieth (SC
member), Lizette Ghazi (SC member), Klemens Angstwurm, Si-
mone Cursiefen, Ana Martins de Silva, Jan-Markus Do¨rr, Irina
Elovaara, Juha-Pekka Era¨linna, Markus Fa¨rkkila¨, Masoud Falah,
Jette Frederiksen, Steven Frequin, Claudio Gobbi, Bernd Griew-
ing, Katrin Gross-Paju, Elisabeth Gulowsen Celius, Christina
Ka¨ding, Claudia Kaiser, Jolanta Kalnina, Christian Kamm, Mar-
gitta Kampman, Keijo Koivisto, Samuel Komoly, Christian
Lampl, Dalia Mickeviciene, Kjell-Morten Myhr, Lina Malciene,
Michael Linnebank, Martin Marziniak, Said Masri, Stefanie
Mu¨ller, Rui Pedrosa, Dieter Po¨hlau, Nils Richter, Thorsten
Rosenkranz, Csilla Rozsa, Ma Jose´ Sa´, Vasco Salgado, Johnny
Samijn, Evert Sanders, Taneli Sarasoja, Okke Sinnige, Bjarne Si-
vertsen,Merja Soilu-Ha¨nninen,Martin Stangel, Egon Stenager, Ol-
iver Stich, Florian Sto¨gbauer, Toomas Toomsoo, Sabine Urbanits,
La´szlo Ve´csei, Freek Verheul, and Uwe K. Zettl.
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